Hot Pursuit     08-Mar-23
Alembic Pharma gets USFDA final approval for Prazosin Hydrochloride capsules
The drug maker announced that it has received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Prazosin Hydrochloride capsules.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Minipress capsules of Pfizer Inc. Prazosin Hydrochloride capsule is indicated for the treatment of hypertension, to lower blood pressure.

Prazosin Hydrochloride capsules has an estimated market size of $50 million for twelve months ending December 2022 according to IQVIA.

Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.

The drug maker reported 29% drop in consolidated net profit to Rs 121.92 crore despite a 18.7% rise in net sales to Rs 1,509.02 crore in Q3 FY23 over Q3 FY22.

The scrip was down 0.88% to Rs 521 on the BSE.

Previous News
  Alembic Pharmaceuticals receives USFDA approval for Dabigatran Etexilate Capsules
 ( Corporate News - 18-Jun-24   18:52 )
  Volumes spurt at Alembic Pharmaceuticals Ltd counter
 ( Hot Pursuit - 20-Jul-23   14:30 )
  Alembic Pharmaceuticals resumes operations at Namthang unit
 ( Corporate News - 01-Feb-24   20:15 )
  Alembic Pharmaceuticals to discuss results
 ( Corporate News - 17-Oct-23   10:13 )
  CRISIL reaffirms ratings of Alembic Pharmaceuticals with 'stable' outlook
 ( Hot Pursuit - 08-Mar-24   11:22 )
  Alembic Pharmaceuticals receives USFDA approval for Macitentan Tablets
 ( Corporate News - 14-Mar-22   12:02 )
  Alembic Pharmaceuticals standalone net profit rises 29.63% in the September 2020 quarter
 ( Results - Announcements 22-Oct-20   17:07 )
  Aleor Dermaceuticals receives USFDA approval for Lidocaine 2.5% and Prilocaine 2.5% Cream
 ( Corporate News - 12-Apr-22   10:20 )
  Alembic Pharmaceuticals consolidated net profit rises 35.37% in the September 2020 quarter
 ( Results - Announcements 23-Oct-20   07:58 )
  Intellect Design Arena Ltd leads losers in 'A' group
 ( Hot Pursuit - 10-May-24   15:00 )
  Alembic Pharma subsidiary receives final approval for lidocaine cream
 ( Hot Pursuit - 12-Apr-22   10:57 )
Other Stories
  RVNL gains on emerging as L-1 bidder for Rs 133-cr railway project
  03-Jul-24   15:38
  Cholamandalam Financial Holdings Ltd leads losers in 'A' group
  03-Jul-24   15:00
  Sakuma Exports Ltd leads losers in 'B' group
  03-Jul-24   14:45
  NTPC power generation climbs 9.5% YoY in Q1
  03-Jul-24   14:41
  Volumes soar at MMTC Ltd counter
  03-Jul-24   14:30
  Oil and Gas shares fall
  03-Jul-24   14:00
  Real Estate stocks edge lower
  03-Jul-24   14:00
  Energy stocks edge lower
  03-Jul-24   14:00
  Sundaram-Clayton gains after board OKs to raise funds upto Rs 400 cr
  03-Jul-24   13:38
  JSW Infra's subsidiary concession agreement V.O. Chidambaranar Port Authority
  03-Jul-24   13:34
Back Top